The Legalization Movement Is Now Fighting Itself
The most revealing cannabis argument this week isn’t between reformers and prohibitionists. It’s between two people who both helped build the legalization movement.
Chris Lindsey spent years at the Marijuana Policy Project. He now runs policy at the American Trade Association for Cannabis and Hemp, and he just published a sharp public criticism of his former organization’s position on intoxicating hemp products, arguing MPP’s campaign to preserve them undermines the state-regulated marijuana systems advocates spent decades building.
That’s a movement arguing with itself about what it was ever trying to accomplish. And the timing could not be worse, with federal restrictions landing in December, manufacturers evaluating inventory, retailers unsure what they can still sell, and investors rethinking which business models survive.
We’ve been away two weeks, and the industry used none of that time to settle down. Washington is still fighting over classification, with the DEA now reviewing a government report about the government’s own review process. Texas and Kansas have made cannabis an election issue. South Dakota’s attorney general says rescheduling shouldn’t touch the state’s medical program. And an NFL-funded study found that changing league policy turns out to be much easier than changing the stigma underneath it.
Different states, different institutions, one shared problem: cannabis is moving into mainstream American life faster than the rules around it can adapt. Let me walk you through it.
The DEA will accept the report. Opponents want to reopen everything.
The rescheduling proceeding hit another procedural crossroads. The DEA says it’s willing to include a recent Government Accountability Office report in the administrative record, a report identifying shortcomings in how federal agencies document parts of their controlled-substance scheduling evaluations. What the DEA doesn’t want is another round of extensive briefing. Opponents of rescheduling disagree and want the administrative law judge to permit additional testimony, document discovery, and further examination of the government’s procedures, which could delay everything.
Sounds like an argument about paperwork. It’s actually about one of the most commercially significant federal marijuana decisions in decades, since the broader proceeding would move marijuana from Schedule I to Schedule III and change how 280E applies to covered activities, potentially restoring ordinary business deductions. For an industry living on compressed margins, that difference is enormous.
But read what the GAO report actually said. It didn’t declare the scientific evaluation invalid, it raised concerns about consistency and documentation in federal scheduling procedures. Those concerns are legitimate, since drug classification should rely on transparent, reproducible decision-making. The legal question is narrower: do administrative shortcomings justify reopening large portions of an already lengthy hearing?
Accepting a document into the record is not a rescheduling decision. A request for more testimony is not proof the government’s science failed. And a procedural pause doesn’t mean reform is dead. It means the process is still contested.
That distinction has real financial consequences. Picture a company projecting improved 2027 after-tax earnings on the assumption Schedule III removes a major tax burden, investors capitalizing those earnings into a higher valuation, and a lender asked to upsize a facility on the projected improvement. If the rule gets delayed, narrowed, or challenged further, that cash flow doesn’t arrive on schedule. Which is why planning should separate existing cash flow from potential regulatory benefit, keeping forecasts conservative while modeling the upside separately. For anyone lending into this, the question isn’t whether rescheduling helps. It’s whether the borrower can perform before the help shows up.
The bottom line: This is a limited procedural concession, not a final decision. Prepare for the tax change without building your survival around an uncertain implementation date.
Texas Senate candidate James Talarico is running on federal legalization.
Cannabis keeps getting more visible in Texas politics. Democratic Senate candidate James Talarico says he’d work toward federal legalization if elected, going well past medical access to adult-use legalization, regulation, and taxation with revenue supporting public-health and public-safety programs. He also opposes broad restrictions on hemp-derived THC, arguing prohibition doesn’t eliminate demand, it just relocates where people buy.
That argument lands hard in Texas specifically, because the state pairs a restrictive marijuana framework with a substantial hemp cannabinoid market, where businesses built operations inside the space federal hemp law created while lawmakers argued about intoxicating products. His opponent, Attorney General Ken Paxton, has taken legal action against municipal decriminalization policies and defended state hemp restrictions, and didn’t respond to the Texas Tribune questionnaire that prompted Talarico’s comments.
Worth staying grounded about what’s actually on offer here, though.
A senator can introduce legislation, build support, and vote. A single senator cannot legalize marijuana nationwide. Any real federal reform needs broad congressional support and the full legislative process.
That doesn’t make the commitment meaningless, because reform increasingly depends on whether officials will prioritize it, and for years politicians offered vague sympathy without committing to specific legislation. Talarico is being explicit. But even full federal legalization wouldn’t automatically erase state licensing or create uniform national product standards, since Congress would still have to address taxation, interstate commerce, regulatory authority, and consumer protection. For Texas businesses the immediate question is narrower and more urgent, which is whether hemp-derived THC products stay lawful, whether distribution networks survive the rule changes, and how to tell a campaign commitment apart from enacted policy. Talarico’s argument also includes allegations about alcohol and tobacco influence, which should be read as political allegations rather than established motive.
The bottom line: Cannabis regulation has moved into the center of a competitive statewide race. The verifiable story is the debate itself, not the outcome.
The hemp civil war is now a public fight between allies.
Back to Lindsey’s criticism, because it deserves unpacking. MPP has urged Congress to replace sweeping hemp restrictions with consumer-protection standards that keep qualifying products available, emphasizing testing, age limits, accurate labeling, and potency controls. Lindsey’s objection is that certain intoxicating hemp products, especially chemically converted cannabinoids and THCA flower, compete with licensed marijuana businesses without carrying comparable regulatory obligations.
Put two businesses side by side. A licensed dispensary carries substantial licensing fees, local approvals, security requirements, inventory tracking, testing costs, specialized banking, and cannabis-specific taxes. A hemp retailer selling intoxicating cannabinoid products through a different framework may face materially different costs depending on jurisdiction and product. They compete for the same customer with very different compliance bills.
Should products producing comparable intoxicating effects face comparable consumer-protection requirements? That’s a legitimate question, and the answer shouldn’t depend on which plant the molecule came from.
Lindsey also raises something usually missing from this debate, which is social equity. State legalization laws frequently included expungement, community reinvestment, or programs addressing harms from past enforcement, and he contends hemp intoxicant markets generally haven’t incorporated comparable obligations. That matters because for many advocates, legalization was never purely a product-market reform, criminal justice and economic opportunity were central. But MPP’s concerns deserve real weight too, since federal restrictions eliminating large portions of the hemp market would disrupt legitimate businesses while demand goes looking for alternatives, and not every hemp cannabinoid product carries identical risk. A low-dose beverage, a highly concentrated edible, and a chemically converted product are not the same thing. The durable framework probably requires both sides to concede, with hemp accepting enforceable consumer-protection standards and licensed operators getting a more equitable competitive environment, while policymakers stop confusing product origin with product risk. What this exposes is that cannabis advocacy is no longer unified around one objective, with some groups prioritizing consumer access, others licensed-market integrity, others criminal justice or public health. Those priorities overlap. They also conflict.
The bottom line: This is a fundamental disagreement over what legalization was supposed to accomplish. Access, fair competition, safety, and equity all matter, and a real framework addresses all four instead of choosing between an unregulated market and a ban.
Kansas wants its tax dollars back, before it has even legalized.
Kansas Democratic gubernatorial candidate Cindy Holscher is making a purely economic case. Kansans are already buying cannabis, they’re just doing some of it in neighboring states, and she says Kansas should stop letting other jurisdictions capture that activity and revenue. She’s also criticizing Republican opponent and state Senate President Ty Masterson for blocking medical-marijuana legislation despite public support.
Geography makes the argument unusually strong here, since Kansas borders Colorado with years of adult-use, Missouri with a regulated recreational market, and Oklahoma with a substantial medical system. For residents near those lines, access means a drive, not abstinence.
Consumers spend elsewhere. Businesses elsewhere collect the revenue. Employees elsewhere earn the wages. Kansas keeps the prohibition and exports the commerce.
But legalization isn’t just opening dispensaries and counting money, since a functioning market requires decisions on licensing, taxation, product testing, local authority, enforcement, and market structure, plus whether to build medical and adult-use simultaneously or in sequence. Other states have already run those experiments, and the lessons are available free: excessive taxes make legal products uncompetitive, restrictive licensing creates shortages, poorly coordinated local rules leave consumers without convenient access, and weak enforcement against unlicensed sellers undermines everyone who complied. For investors, Kansas is a potential future market rather than an opportunity, and nobody should assign meaningful value to licenses that don’t exist, since a gubernatorial win doesn’t guarantee legislative passage. Still worth monitoring, because new markets create demand for deposit services, payment infrastructure, real estate and equipment financing, and working capital, with the strongest borrowers being the ones who can demonstrate legitimate ownership, adequate capitalization, and a disciplined operating plan.
The bottom line: Legalization is increasingly framed as a competitiveness issue. Not whether adults should consume, but whether a state benefits from prohibiting something residents can buy twenty minutes away.
The NFL changed its policy. The stigma didn’t follow.
A new NFL-funded study found attitudes toward cannabis becoming more open as athletes and medical professionals reconsider its role in pain management. It also found a problem that doesn’t vanish when league policy changes, which is that stigma still interferes with honest communication between athletes and medical staff.
That distinction is the whole story. A league can revise its prohibited-substances policy, fund research, and change disciplinary procedures, and none of that automatically changes what coaches, trainers, physicians, and players actually believe. If a player thinks disclosure could damage his reputation or career, he won’t disclose.
That’s a healthcare problem, not a policy problem. Clinicians need accurate information about what patients consume, since cannabis can interact with medications, affect coordination, and influence symptoms relevant to treatment. A doctor working from incomplete information can’t assess risk.
The study suggests some younger or research-oriented clinicians are increasingly willing to consider cannabis in pain-management discussions, which doesn’t establish it as universally safer or more effective than opioids. Comparative risk depends on patient, condition, product, dose, and circumstance. Opioids can be appropriate and effective when carefully prescribed, and cannabis carries its own risks including impairment and dependence. Athletes are a particularly complicated population, with repeated physical stress, recovery central to performance, pain management affecting career longevity, and medical decisions made under competitive pressure, where a player may underreport symptoms while a trainer faces pressure to return him to play. The broader implication is that evidence-based education beats stigma, because if athletes understand the actual risks they may talk openly, and if medical staff can ask without implying misconduct they get better clinical information. That principle extends well past sports into employers, healthcare systems, and insurers dealing with safety-sensitive work. Normalization doesn’t require pretending marijuana is harmless, just discussing its risks without exaggeration. And for the industry, the opportunity is supporting rigorous research rather than leaning on athlete testimonials, since personal experience identifies promising questions but can’t substitute for controlled evidence.
The bottom line: Stigma is weakening, but distrust still breaks the conversation between athletes and their doctors. The next step isn’t looser restrictions, it’s reliable evidence and honest disclosure.
South Dakota says rescheduling won’t dismantle its medical program.
South Dakota Attorney General Marty Jackley issued a legal opinion concluding that federal rescheduling is unlikely to significantly affect the state’s medical-cannabis program, with state-licensed medical businesses able to continue operating under the applicable federal and state registration framework. Some lawmakers had questioned whether the federal change would undermine the legal basis for the program, and Jackley rejects that premise.
Sounds uneventful. In cannabis regulation, uneventful is valuable.
The distinction matters because cannabis involves overlapping legal authorities, where states run licensing programs and federal law controls substance classification with separate requirements, and those systems can interact without becoming identical. A state license doesn’t automatically satisfy every federal requirement, and a federal scheduling change doesn’t erase state licensing authority.
Don’t read this as a nationwide guarantee. Washington State has been exploring a certification process because its licensing structure doesn’t neatly match certain federal medical-cannabis categories. Same federal policy, completely different implementation questions.
That contrast is exactly why operators need state-specific legal analysis rather than assuming a federal announcement means the same thing everywhere, with financial institutions needing to understand the specific licenses and activities of individual borrowers, and investors distinguishing a state’s interpretation from a binding federal determination. The opinion also shows why state-federal coordination matters, because a company needs to know which registrations are required, what activities are permitted, and whether existing procedures remain valid. Uncertainty costs money in delayed investments, hesitant lenders, insurers demanding extra documentation, and regulators receiving conflicting interpretations. A clear legal opinion reduces some of that. It doesn’t resolve everything.
The bottom line: Regulatory continuity in South Dakota is a good sign, not proof every cannabis business nationwide gets the same treatment. State-specific licensing and federal registration both still apply.
A former NFL player wants THC drinks regulated like alcohol.
Former NFL player Micah Hyde argues in an opinion piece that Congress should regulate intoxicating hemp drinks rather than eliminate them, informed by his experience as a professional athlete and his involvement in the beverage business. He describes growing dissatisfied with alcohol during his career and eventually seeing hemp beverages as an alternative, and his argument centers on consumer choice: alcohol is legal for adults inside an established framework with manufacturer rules, retailer licensing, age restrictions, and public-health risks managed through regulation rather than a ban.
He thinks hemp THC beverages deserve a comparable approach, though comparable isn’t identical, since the substances have different pharmacological effects and THC dosing presents real challenges with delayed onset and variable individual response. Those differences justify product-specific standards.
The useful part of his argument isn’t the alcohol comparison. It’s the premise underneath it, that prohibition shouldn’t be treated as the only alternative to an inadequately regulated market.
That lands at a critical moment, with December restrictions threatening many existing products, manufacturers facing uncertainty on formulations and inventory, retailers possibly pulling products, and consumers losing access to brands they’ve been buying legally. Hyde’s proposed framework covers age verification, testing, clear labeling, serving-size standards, and responsible marketing, measures that would help separate legitimate beverage businesses from operators selling poorly characterized products. The commercial stakes are real, since THC beverages compete for occasions alcohol has owned, dinner parties, social gatherings, sporting events, restaurants, weekends. None of which establishes cannabis beverages as universally safer than alcohol, and one athlete’s experience doesn’t prove a medical benefit. For investors the challenge is whether the opportunity survives federal regulation at all, because strong branding and consumer demand matter little if the products no longer qualify for lawful distribution. For policymakers it’s balancing consumer protection against the consequences of erasing an existing category, and the strongest rules reflect actual product risk rather than whether a cannabinoid came from hemp or marijuana.
The bottom line: This is advocacy, but it raises a fair question. Can Congress set strict safety and age-access standards without eliminating the category?
Idaho’s cannabis fight is really about who gets to make the decision.
Idaho voters face a constitutional question in November: should citizens keep the ability to pursue marijuana legalization through ballot initiatives, or should that authority belong exclusively to the legislature? House Joint Resolution 4 would amend the state constitution to reserve the power to legalize marijuana and certain other psychoactive substances to lawmakers. NORML Deputy Director Paul Armentano argues in an opinion piece that this is an attack on direct democracy.
The issue is bigger than cannabis. Idaho currently lets citizens pursue changes in state law through initiatives, giving voters a pathway when lawmakers won’t act, and HJR 4 would close that pathway for the covered substances. Supporters say drug policy is too complicated for initiatives shaped by commercial campaigns, and that lawmakers are better equipped to examine evidence, hear testimony, and build detailed regulations. That argument has genuine merit, since initiatives are expensive, can be driven by wealthy donors, and complex regulatory systems are hard to design in short ballot language.
Opponents see the other risk. Surrender the initiative power and voters may be unable to act even when public opinion shifts dramatically. Several states legalized adult-use precisely because citizens had a route around an unwilling legislature.
It wouldn’t necessarily prevent future legalization, since lawmakers could still pass legislation, but citizens would lose the independent path. For businesses the implications are indirect but real, because political structures shape market opportunities, and a state where citizens can initiate reform has a different trajectory than one where lawmakers hold exclusive authority. Investors evaluating emerging markets need to understand that distinction, since public support alone doesn’t create a legal industry, the mechanism for converting support into law is what matters. And the question splits in interesting ways, because a voter can oppose legalization and still believe citizens should retain the power to propose it, while another can support medical cannabis while preferring legislative regulation. Those aren’t contradictory positions.
The bottom line: Idaho is voting on how future reform can happen, not whether cannabis becomes legal now. That makes it more consequential than a conventional marijuana ballot measure.
Wednesday closing
There was a time when every cannabis development could be scored by one question: did it move legalization forward? That made sense when criminalization and political resistance were the main obstacles.
Look at today’s stories and that scoreboard stops working. The DEA isn’t debating whether marijuana has medical value, it’s debating the procedures for changing a classification. South Dakota isn’t deciding whether to create a medical program, it’s figuring out how federal rules interact with the one already running. Texas and Kansas are arguing about cannabis as an electoral and economic issue. The NFL is reconsidering decades of stigma. And the hemp industry is fighting with itself over whether its market should be preserved, transformed, or folded into licensed marijuana. Those are the problems of an industry approaching maturity, and maturity requires more than political momentum. It requires institutions that work.
That last point deserves weight, because cannabis has spent years treating federal reform as the solution to its financial problems. Some reforms genuinely would help, since 280E relief could improve after-tax earnings, clearer rules could cut uncertainty, and better financial access could reduce friction. But none of it makes an unprofitable business profitable. Weak management stays weak management, a badly structured acquisition stays badly structured, excessive debt still has to be serviced, and a manufacturer whose products face a ban still needs a contingency plan. The industry can’t keep betting that the next federal announcement solves everything, which is especially true in hemp, where a company can have excellent branding, real demand, and an expanding distribution network, and still face an existential problem if the products behind its revenue become unlawful. Marketing doesn’t fix that. Regulatory strategy, product development, capital planning, and execution do.
The same applies to legalization itself, because opening a market is the beginning, not the end. A successful one needs sensible taxation, enforceable standards, viable licensing, and a competitive environment where compliant businesses actually survive, or you get an industry that’s technically lawful and economically unsustainable, which is a policy failure as much as a business one. The political stories make the companion point, that public opinion matters but institutions determine how opinion becomes law. Texas voters can elect reformers, Kansas voters can demand change, Idaho voters can preserve their initiative power, and every state still needs a workable framework afterward. Political support creates the opportunity. Implementation decides the outcome. Legalization created the opening, regulation shapes the market, and execution determines who’s still standing.
That’s what this newsletter is for.
What’s the biggest regulatory challenge your operation is facing right now? Hit reply, I read every response and it shapes what I cover next week.
If this was useful, forward it to someone in the cannabis space or hit the restack button on Substack. It’s how this community grows.